Detection of EGFR mutational profile by direct dideoxy sequencing in cytology and non-cytology biopsy samples

Pathology

Volumn 46, Issue 4, 2014, Pages 283-288

  Leslie, Connull ^a   Giardina, Tindaro ^a   Carrello, Amerigo ^a   Spagnolo, Dominic V ^a,b   Amanuel, Benhur ^a,b  

^a PATHWEST LABORATORY MEDICINE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cytology; Direct sequencing; EGFR; Lung carcinoma

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; CARCINOMA; CYTODIAGNOSIS; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENETICS; HUMAN; LUNG LAVAGE; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PERITONEUM LAVAGE; POLYMERASE CHAIN REACTION; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; BRONCHOALVEOLAR LAVAGE; CARCINOMA; CYTODIAGNOSIS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERITONEAL LAVAGE; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84902147985     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000093     Document Type: Article

References (27)

1. Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008;26:1742-51.
2. Nicholson RI, Gee J M W, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(Suppl 4):S9-15.
3. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
4. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
5. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancer from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11.
6. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23.
7. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-65.
8. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signalling pathway in cancers. Int J Cancer 2006;118:257-62.
9. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
10. Brachtel EF, Iafrate AJ, Mark EJ, Deshpande V. Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma. Diagn Cytopathol 2007;35:257-62.
11. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary: Classification of Lung Adenocarcinoma. J Thoracic Oncol 2011;6:244-85.
12. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12:7232-41.
13. Gazdar AF, Minna JD. Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops. Cancer Prev Res 2008;1:156-60.
14. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet 2012;13:e23-31.
15. Smouse JH, Cibas ES, Janne PA, Joshi VA, Zou KH, Lindeman NI. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of non-small cell lung cancer. Cancer Cytopathol 2009;117:67-72.
16. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumour subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011;6:451-8.
17. Aisner DL, Deshpande C, Baloch Z, et al. Evaluation of EGFR mutation status in cytology specimens: an institutional experience. Diagn Cytopathol 2013;41:316-23.
18. Webb S, Thomas M, Metcalf C, et al. EGFR mutation testing in NSCLC: patterns of care and outcomes in Western Australia. Asia-Pac J Clin Oncol 2009;5:66-71.
19. Chowdhuri SR, Xi L, Pham TH, et al. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol 2011;25:48-555.
20. Santos GD, Saieg MA, Geddie W, Leighl N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma. Cancer Cytopathol 2011;119:80-91.
21. Sun PL, Jin Y, Kim H, et al. High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas. Cancer Cytopathol 2013;121:311-9.
22. Tam IY, Leung EL, Tin VP, et al. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther 2009;8:2142-51.
23. Chen Z, Feng J, Saldivar J-S, et al. EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids. Oncogene 2008;27:4336-43.
24. Wu S-G, Chang Y-L, Hsu Y-C, et al. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. Oncologist 2008;13:1276-84.
25. Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25:587-95.
26. Malapelle U, Bellevicine C, Zeppa P, Palombini L, Troncone G. Cytologybased gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review. Diagn Cytopathol 2011;39:703-10.
27. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancersearching for the ideal method. Clin Cancer Res 2007;13:4954-5.